In a nutshell This study looked at the effectiveness of the standard pediatric chemotherapy regimen in children and young adults. The study concluded that adolescents and children have similar outcomes when treated with the pediatric chemotherapy regimen. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. It is...
Read MoreHodgkin’s lymphoma Posts on Medivizor
Novel treatments for patients with relapsed Hodgkin Lymphoma following autologous stem cell transplantation
In a nutshell This study examined the effect of new treatments for patients who have relapsed after an autologous stem cell transplantation. The authors concluded that patients treated with new therapies, including brentuximab vedotin (Adcetris), have significantly better outcomes. Some background Hodgkin lymphoma (HL) is generally...
Read MoreTreatment Guidelines for classical Hodgkin Lymphoma in adults
In a nutshell This article reviewed the NCCN guidelines for the treatment of classical Hodgkin lymphoma in adults 18 years of age or older. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. Most HL occurs in young people between 15 and 30 years old. The most common treatments are chemotherapy and radiation....
Read MoreUsing white blood cell counts to predict relapse after autologous stem cell transplantation in children and young adults with Hodgkin lymphoma
In a nutshell This study examined the use of lymphocyte and monocyte blood counts to predict the outcome of autologous stem cell (immature blood cell) transplantation in children and young adults. The study concluded that the lymphocyte/monocyte ratio can be used to predict a likely relapse following autologous stem cell transplantation. Some...
Read MoreThe real-world effectiveness of brentuximab vedotin
In a nutshell This study looked at the effects of brentuximab vedotin (Adcetris) in a real-world setting. The study concluded that this is a valid treatment for patients with relapsed Hodgkin lymphoma, and is especially helpful in elderly patients. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However,...
Read MoreColon Cancer Patient Advocate Shares Her Story
In April, the American Association for Cancer Research (AACR) held a free education event on cancer called Progress and Promise Against Cancer in Washington, D.C. Surrounded by experts in cancer research, Kim Hall Jackson shared her patient story. One evening in 2008, Jackson, an event planner, was running the mayor’s inaugural event in...
Read MoreGuest Post: Hodgkin’s Lymphoma and My Stem Cell Transplant Experience
“I am 24 years old. Last year on January 15th 2016, I was diagnosed with Stage 2A Classical Nodular Sclerosing Hodgkin’s Lymphoma. I had 12 cycles of ABVD chemotherapy over 6 months and went into complete remission on August 8th, 2016. A few weeks before my wedding, on November 4th 2016 I had my first follow up CT scan which showed enlarged...
Read MoreKnowledge is Power: Help For People With Hodgkin’s Lymphoma
“Family and friends can be great sources of support but truth be told, no one can ever really know what you are going through other than those who have been there themselves….” ~Rachele Chaar Ghosn For Rachele Chaar Ghosn, a 24-year-old woman with Hodgkin’s Lymphoma, finding others going through treatment for Hodgkins was paramount....
Read MoreCarboplatin as a replacement for cisplatin in DHAP chemotherapy for Hodgkin lymphoma
In a nutshell The authors investigated the use of carboplatin instead of cisplatin in the DHAP chemotherapy regimen. The authors concluded that carboplatin is less toxic that cisplatin, and may be a good substitute. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However, some patients do not respond to first...
Read MoreRecommendations for the treatment of Hodgkin lymphoma
In a nutshell This review outlined the current recommended treatment options for different stages of Hodgkin Lymphoma as well as highlighted promising new experimental drugs. Some background Hodgkin Lymphoma (HL) is generally considered a curable disease. Over 90% of patients diagnosed with early stage favorable HL will be cured. However, there...
Read MoreBone marrow biopsy versus PET/CT scan for staging classical Hodgkin lymphoma
In a nutshell This study examined whether bone marrow biopsies are necessary if PET scans are used to stage classical Hodgkin lymphoma. The study concluded that patients can safely be staged with PET/CT scans without bone marrow biopsy. Some background Hodgkin lymphoma (HL) is widely considered a curable disease. Between 4 and 11% of patients with...
Read MoreLong term follow-up study of reduced intensity treatments for early stage Hodgkin lymphoma
In a nutshell This study provided a long-term follow-up of patients diagnosed with early-stage Hodgkin lymphoma. The study concluded that current strategies for reduced intensity treatment of early-stage Hodgkin lymphoma are generally safe and effective. Some background Hodgkin lymphoma (HL) is generally considered a curable disease....
Read More
